CPC A61L 27/60 (2013.01) [A61F 2/10 (2013.01); A61L 27/18 (2013.01); A61L 27/20 (2013.01); A61L 27/3804 (2013.01); A61L 27/3813 (2013.01); A61L 27/3839 (2013.01); A61L 27/3891 (2013.01); A61L 27/52 (2013.01); B29C 64/106 (2017.08); B33Y 10/00 (2014.12); B33Y 70/00 (2014.12); B33Y 80/00 (2014.12); C08L 5/08 (2013.01); C08L 89/06 (2013.01); C12N 5/0698 (2013.01); G01N 33/502 (2013.01); G01N 33/5044 (2013.01); A61F 2210/0076 (2013.01); A61F 2240/001 (2013.01); A61L 2300/64 (2013.01); A61L 2430/34 (2013.01); B29K 2075/00 (2013.01); B29K 2105/0061 (2013.01); C12N 2502/091 (2013.01); C12N 2502/092 (2013.01); C12N 2502/094 (2013.01); C12N 2502/1305 (2013.01); C12N 2502/1323 (2013.01); C12N 2533/30 (2013.01); C12N 2533/54 (2013.01); C12N 2533/80 (2013.01)] | 18 Claims |
1. A method of making a skin substitute product, comprising the steps of:
(a) depositing a first layer comprising live mammalian adipocytes in a first hydrogel carrier on a substrate; then
(b) depositing a second layer on said first layer, said second layer comprising live mammalian fibroblast cells and live mammalian follicle dermal papilla cells in a second hydrogel carrier; and then
(c) depositing a third layer on said second layer, said third layer comprising live mammalian keratinocytes and live mammalian melanocytes in a third hydrogel carrier,
wherein said live mammalian adipocytes are human adipocytes, said live mammalian fibroblast cells are human fibroblast cells, said live mammalian follicle dermal papilla cells are human follicle dermal papilla cells, said live mammalian keratinocytes are human keratinocytes, and said live mammalian melanocytes are human melanocytes.
|